A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

NCT02661100 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Drug unavailable

Conditions

Non Small Cell Lung Cancer
Advanced Triple Negative Breast Cancer
Small Cell Lung Cancer
Urothelial Cancer
Mesothelioma
Malignant Melanoma

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: CDX-1401
BIOLOGICAL: Poly-ICLC

Sponsor

Case Comprehensive Cancer Center